Journal Mobile Options
Table of Contents
Vol. 101, No. 1, 2003
Issue release date: 2003
Cytogenet Genome Res 101:17–23 (2003)

Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)

Hansford L.M. · Smith S.A. · Haber M. · Norris M.D. · Cheung B. · Marshall G.M.
aChildren’s Cancer Institute Australia for Medical Research; bCentre for Children’s Cancer and Blood Disorders, Sydney Children’s Hospital, Sydney (Australia)

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


We report the isolation and characterization of human contactin 4 (CNTN4), a brain-derived, immunoglobulin superfamily molecule-2 (alias BIG-2) as a candidate gene responsible for the differentiation potential of human neuroblastoma cells. Northern blot analysis showed highest CNTN4 expression in testes, thyroid, small intestine, uterus and brain. Induction of CNTN4 mRNA expression in human neuroblastoma tumor cells treated with retinoic acid correlated with a block in retinoid-induced neuritogenesis. Our findings suggest a role for human contactin 4 protein in the response of neuroblastoma cells to differentiating agents.   

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Balmer JE, Blomhoff R: Gene expression regulation by retinoic acid. J Lipid Res 43:1773–1808 (2002).
  2. Bauer D, Müller H, Reich J, Riedel H, Ahrenkiel V, Warthoe P, Strauss M: Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR). Nucl Acids Res 21:4272–4280 (1993).
  3. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159 (1987).
  4. Drwinga HL, Toji LH, Kim CH, Greene AE, Mulivor RA: NIGMS human/rodent somatic cell hybrid mapping panels 1 and 2. Genomics 16:311–314 (1993).
  5. Kleinschmidt-DeMasters BK, Orr EA, Savelieva E, Owens GC, Kruse CA: Paucity of retinoic acid receptor alpha (RAR?) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression. J Neurooncol 41:31–42 (1999).
  6. Marshall GM, Cheung B, Stacey KP, Camacho ML, Simpson AM, Kwan E, Smith S, Haber M, Norris MD: Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene 11:485–491 (1995).
  7. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP: Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New Eng J Med 341:1165–1173 (1999).
  8. Phimister E, Kiely F, Kemshead JT, Patel K: Expression of neural cell adhesion molecule (NCAM) isoforms in neuroblastoma. J Clin Pathol 44:580–585 (1991).
  9. Sidell N, Altman A, Haussler MR, Seeger RC: Effects of retinoic acid (RA) on the growth and the phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res 148:21–30 (1983).
  10. Yoshihara Y, Kawasaki M, Tani A, Tamada A, Nagata S, Kagamiyama H, Mori K: BIG-1: A new TAG-1/F3-related member of the immunoglubulin superfamily with neurite outgrowth-promoting activity. Neuron 13:415–426 (1994).
  11. Yoshihara Y, Kawasaki M, Tamada A, Nagata S, Kagamiyama H, Mori K: Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: Four members of an axonal-associated cell adhesion molecule subgroup of the immunoglobulin superfamily. J Neurobiol 28:51–69 (1995).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50